CADL NASDAQ
Candel Therapeutics, Inc.
1W: -5.3%
1M: -1.1%
3M: +53.9%
YTD: +77.9%
1Y: +37.9%
3Y: +674.4%
$9.68
-0.28 (-2.81%)
Weekly Expected Move ±8.2%
$8
$9
$10
$10
$11
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$3.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$709.3M
52W Range4.35-11.36
Volume1,596,317
Avg Volume1,939,056
Beta-0.51
Dividend—
Analyst Ratings
Company Info
CEOPaul-Peter Tak
Employees55
SectorHealthcare
IndustryBiotechnology
IPO Date2021-07-27
Websitecandeltx.com
117 Kendrick Street
Needham, MA 02494
US
Needham, MA 02494
US
617 916 5445
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Latest News
Candel Therapeutics (NASDAQ:CADL) Trading 8.1% Higher – Here’s Why
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Sims Mark E. | A-Award | 285,000 | $10.03 | 2026-07-06 |
| Sims Mark E. | 0 | — | 2026-07-06 | |
| Manning Paul B | A-Award | 2,199 | $10.30 | 2026-06-30 |
| PAPA JOSEPH C | A-Award | 1,331 | $10.30 | 2026-06-30 |
| Loggia Nicoletta | A-Award | 381 | $10.30 | 2026-06-30 |